TO BE PUBLISHED March 2026
Starting from:
£99 + VAT
Format: DOWNLOADABLE PDF
This conference will examine next steps for the development, regulation, and implementation of AI in healthcare.
Widening application & funding
It will bring together stakeholders and policymakers to discuss the future for AI in the NHS as it moves from the pilot phase into wider use, with ambitions laid out in the 10 Year Health Plan for the NHS to be the most AI-enabled healthcare system in the world.
Delegates will examine opportunities for innovation and growth, and how they can be achieved, alongside priorities for safety and an evidence-based approach, as well as questions around workforce capabilities, equity and public confidence.
With £10bn investment for technology and digital transformation committed at the 2025 Spending Review and £300m investment announced for NHS technology in the Autumn Budget, attendees will consider approaches for utilising and channelling investment. This includes next steps for improving digital capability and readiness, infrastructure and interoperability of technology in the NHS, and achieving the safe and ethical application of AI going forward.
Regulation & oversight
Priorities for regulation will be examined, as a National Commission into the Regulation of AI in Healthcare is appointed to review existing arrangements and to recommend a new framework.
Delegates will consider the future for proportionate risk regulation in this area, how regulatory gaps can be addressed, and how innovation can be encouraged while maintaining safety, consistency and public confidence, looking at emerging technologies such as ambient voice systems, and commitments in the Life Sciences Sector Plan.
With AI scribes and ambient voice technologies being positioned as a key tool in improving NHS productivity, delegates will discuss options for putting regulation in place quickly to enable safe deployment, whilst addressing concerns with the evidence-base, as well as around accuracy, bias and inequity with accents and dialects, and data security.
There will also be a focus on requirements for human oversight of automated decision-making, and how these may affect the design of AI-assisted triage and eligibility assessments.
Discussion will also look at how AI can be used to improve the quality of care, including supporting organisations with learning from patient safety incidences, and engaging with the Patient Safety Incidents Response Framework.
Scalability, learning from pilots & data
Delegates will discuss latest thinking on tackling challenges for bringing forward AI tools from pilot phases to wider adoption. These include addressing issues related to data fragmentation, gaps in digital infrastructure, and integration with legacy systems, as well as tackling cultural and organisational barriers such as siloed working, and putting in place the operational capacity for implementing change.
Emerging insights from the first phase of MHRA’s AI Airlock programme will be considered, including concerns raised around AI hallucinations, and tensions created where AI performance is impacted by accuracy of health records.
Delegates will also discuss practical steps for implementing centralised and standardised deployment in multiple trusts, looking at the NHS England AI Deployment Platform Pilot, and approaches to reducing costs and duplication of processes often associated with individual pilot projects. Initiatives from MHRA, NICE and NHS England in supporting the safe scaling of diagnostic AI tools will be considered, with discussion on developing new approval routes for market access, and implications for investment confidence and sector growth.
Sessions will also examine data use and governance in light of the Data (Use and Access) Act 2025, and priorities for research collaboration such as the way forward for more flexible consent regimes, supporting broader clinical trials, and developing governance arrangements that maintain public confidence.
Use cases, integration, patient engagement & workforce priorities
There will be discussion on enabling AI use cases in precision medicine, including personalising treatment pathways, accelerating drug discovery, and transparency with patients over how AI is being used to treat their conditions.
In looking at opportunities for supporting patient choice, empowerment and autonomy, we expect a focus on the future use of AI in the NHS App as well as potential pilots next year for generative AI symptom checkers and triage, with discussion on the levels of health and digital literacy required for safe implementation and delivery.
Support for the workforce with skills in managing data and interpreting AI insights will be considered - as well as the role of leadership in putting in place workforce capabilities for operating AI when time and resources are pressured. Areas for discussion include managing hesitancy with uptake, and adapting to evolving job roles as AI is deployed, and strategic preparations for the impact of AI on the wider system and capacity planning.
All delegates will be able to contribute to the output of the conference, which will be shared with parliamentary, ministerial, departmental and regulatory offices, and more widely. This includes the full proceedings and additional articles submitted by delegates. As well as key stakeholders, those already due to attend include a parliamentary pass-holder from the House of Commons and officials from the Medicines and Healthcare products Regulatory Agency; Welsh Government; and The Scottish Government.
